Continuous antibiotic infusion in children

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522809-38-00

Enrollment

150

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection disease

Brief summary

Duration of hospital stay / fever / antibiotic treatment, Readmission to hospital, Possible relapse (defined separately for each patient case)

Interventions

DRUGPiperacillin/Tazobactam Kalceks 2 g/0

DRUG25 g infuusiokuiva-aine

DRUGliuosta varten

DRUGBenzylpenicillin Fresenius Kabi 1

DRUG2 g (2 milj. IU) injektio-/infuusiokuiva-aine liuosta varten

DRUGVancosan 500 mg

DRUGInfuusiokuiva-aine

DRUGCloxacillin Navamedic 2 g injektio-/infuusiokuiva-aine liuosta varten

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Duration of hospital stay / fever / antibiotic treatment, Readmission to hospital, Possible relapse (defined separately for each patient case)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 17, 2026